Companies: 10,795·Total market cap: $144.5T
Vivos Therapeutics, Inc.

Vivos Therapeutics, Inc.

VVOSNASDAQHealthcare● Active
$0.86
$-0.00(-0.54%)
Market Cap$5063809
P/E Ratio—
52W High$7.95
52W Low$0.545
SEC Filings

Vivos Therapeutics, Inc. (VVOS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001716166 · VVOS · NASDAQ · as of Jun 8, 2026

Filing snapshot

270
Total Filings
8-K
Latest Form
2026-06-08
Most Recent
2020
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001716166 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-04-15
Fiscal Year End
Apr 15, 2026
Accession No.
0001493152-26-016854
Primary Document
form10-k.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001716166 · Accession 0001493152-26-016854

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-20
View 10-Q on SEC
8-KCurrent Report
8-K
2026-06-08Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
8-K
2026-06-08
View
10-QQuarterly Report
10-Q
2026-05-20
View
NT 10-QNT 10-Q
NT 10-Q
2026-05-15
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-15
View
EFFECTEFFECT
EFFECT
2026-05-08
View
424B3424B3
424B3
2026-05-08
View
CORRESPCORRESP
CORRESP
2026-05-06
View
S-3/AS-3/A
S-3/A
2026-04-30
View
8-KCurrent Report
8-K
2026-04-22
View
8-KCurrent Report
8-K
2026-04-15
View
10-KAnnual Report
10-K
2026-04-15
View
3Initial Statement of Beneficial Ownership
3
2026-04-10
View
8-KCurrent Report
8-K
2026-04-03
View
SCHEDULE 13DSCHEDULE 13D
SCHEDULE 13D
2026-04-02
View
NT 10-KNT 10-K
NT 10-K
2026-03-31
View
Showing 1–15 of 232 filingsForm 4 / 144 hidden· 270 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001716166  |  Exchange: NASDAQ · Healthcare

Vivos Therapeutics, Inc. (NASDAQ: VVOS) has submitted 270 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001716166, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Vivos Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Vivos Therapeutics, Inc. 10-K was filed on 2026-04-15 for fiscal year ending 2026. Historical VVOS 10-K annual reports are available from 2017 through 2026.

Investors researching Vivos Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
ANL SEC Filings →COCH SEC Filings →LPCN SEC Filings →ADGM SEC Filings →OSRH SEC Filings →AMS SEC Filings →CODX SEC Filings →ALUR SEC Filings →
→ VVOS Financials→ VVOS Earnings→ VVOS Insider Trades

Frequently Asked Questions

VVOS SEC Filings · 8 questions

Vivos Therapeutics, Inc. (VVOS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 270 filings and access original documents at no cost. Vivos Therapeutics, Inc.'s CIK is 0001716166.

VVOS SEC filingsVivos Therapeutics, Inc. SEC documentsfind VVOS 10-K